1. Home
  2. COO vs CINGW Comparison

COO vs CINGW Comparison

Compare COO & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COO
  • CINGW
  • Stock Information
  • Founded
  • COO 1980
  • CINGW N/A
  • Country
  • COO United States
  • CINGW United States
  • Employees
  • COO N/A
  • CINGW 13
  • Industry
  • COO Ophthalmic Goods
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • COO Health Care
  • CINGW Health Care
  • Exchange
  • COO Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • COO N/A
  • CINGW N/A
  • IPO Year
  • COO N/A
  • CINGW 2021
  • Fundamental
  • Price
  • COO $99.86
  • CINGW $0.05
  • Analyst Decision
  • COO Buy
  • CINGW
  • Analyst Count
  • COO 12
  • CINGW 0
  • Target Price
  • COO $117.00
  • CINGW N/A
  • AVG Volume (30 Days)
  • COO 1.3M
  • CINGW N/A
  • Earning Date
  • COO 12-05-2024
  • CINGW N/A
  • Dividend Yield
  • COO N/A
  • CINGW N/A
  • EPS Growth
  • COO 30.26
  • CINGW N/A
  • EPS
  • COO 1.80
  • CINGW N/A
  • Revenue
  • COO $3,804,100,000.00
  • CINGW N/A
  • Revenue This Year
  • COO $9.76
  • CINGW N/A
  • Revenue Next Year
  • COO $7.61
  • CINGW N/A
  • P/E Ratio
  • COO $56.31
  • CINGW N/A
  • Revenue Growth
  • COO 8.25
  • CINGW N/A
  • 52 Week Low
  • COO $82.22
  • CINGW N/A
  • 52 Week High
  • COO $112.38
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • COO 30.34
  • CINGW N/A
  • Support Level
  • COO $99.77
  • CINGW N/A
  • Resistance Level
  • COO $103.89
  • CINGW N/A
  • Average True Range (ATR)
  • COO 2.29
  • CINGW 0.00
  • MACD
  • COO -0.52
  • CINGW 0.00
  • Stochastic Oscillator
  • COO 2.28
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: